ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Generalized Anxiety Disorder (GAD)
Conditions
Generalized Anxiety Disorder (GAD)
Trial Timeline
Apr 29, 2025 → Nov 1, 2026
NCT ID
NCT06846320About ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT) is a phase 2 stage product being developed by AbbVie for Generalized Anxiety Disorder (GAD). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06846320. Target conditions include Generalized Anxiety Disorder (GAD).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06846320 | Phase 2 | Recruiting |
Competing Products
20 competing products in Generalized Anxiety Disorder (GAD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + placebo | Eli Lilly | Phase 2/3 | 65 |
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Perampanel + Placebo comparator | Eisai | Phase 3 | 77 |
| zonisamide | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Perampanel | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Cenobamate | Ono Pharmaceutical | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Approved | 85 |
| Ixekizumab | Eli Lilly | Approved | 85 |
| eszopiclone + eszopiclone + Placebo | Sumitomo Pharma | Phase 2 | 52 |
| Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment | Sumitomo Pharma | Approved | 85 |
| Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day | AbbVie | Phase 2 | 52 |
| ABBV-932 + Placebo | AbbVie | Phase 1 | 33 |
| Escitalopram | AbbVie | Approved | 85 |
| Adalimumab | AbbVie | Phase 3 | 77 |
| Quetiapine fumarate + Paroxetine | AstraZeneca | Phase 3 | 77 |